The U.S. health care sector continues to underperform on Wall Street, with the benchmark S&P 500 Health Care Sector Index down 3.1% year to date by market price as of July 22. That' ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...